Andrea C Mesías1, Natalia Sasoni2, Diego G Arias2, Cecilia Pérez Brandán1, Oliver C F Orban3, Conrad Kunick3, Carlos Robello4, Marcelo A Comini5, Nisha J Garg6, M Paola Zago7. 1. Instituto de Patología Experimental, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Salta, Argentina. 2. Instituto de Agrobiotecnología del Litoral, Universidad Nacional del Litoral - CONICET, Santa Fe, Argentina. 3. Technische Universität Braunschweig, Institut für Medizinische und Pharmazeutische Chemie, Beethovenstraße 55, D-38106 Braunschweig, Germany. 4. Unidad de Biología Molecular, Institut Pasteur de Montevideo, and Departamento de Bioquímica, Facultad de Medicina, Uruguay. 5. Redox Biology of Trypanosomes - Institut Pasteur de Montevideo, Montevideo, Uruguay. 6. Departments of Microbiology and Immunology and Pathology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: nigarg@utmb.edu. 7. Instituto de Patología Experimental, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Salta, Argentina. Electronic address: mpzago@conicet.gov.ar.
Abstract
BACKGROUND: Chagas cardiomyopathy, caused by Trypanosoma cruzi infection, continues to be a neglected illness, and has a major impact on global health. The parasite undergoes several stages of morphological and biochemical changes during its life cycle, and utilizes an elaborated antioxidant network to overcome the oxidants barrier and establish infection in vector and mammalian hosts. Trypanothione synthetase (TryS) catalyzes the biosynthesis of glutathione-spermidine adduct trypanothione (T(SH)2) that is the principal intracellular thiol-redox metabolite in trypanosomatids. METHODS AND RESULTS: We utilized genetic overexpression (TryShi) and pharmacological inhibition approaches to examine the role of TryS in T. cruzi proliferation, tolerance to oxidative stress and resistance to anti-protozoal drugs. Our data showed the expression and activity of TryS was increased in all morphological stages of TryShi (vs. control) parasites. In comparison to controls, the TryShi epimastigotes (insect stage) recorded shorter doubling time, and both epimastigotes and infective trypomastigotes of TryShi exhibited 36-71% higher resistance to H2O2 (50-1000 μM) and heavy metal (1-500 μM) toxicity. Treatment with TryS inhibitors (5-30 μM) abolished the proliferation and survival advantages against H2O2 pressure in a dose-dependent manner in both TryShi and control parasites. Further, epimastigote and trypomastigote forms of TryShi (vs. control) T. cruzi tolerated higher doses of benznidazole and nifurtimox, the drugs currently administered for acute Chagas disease treatment. CONCLUSIONS: TryS is essential for proliferation and survival of T. cruzi under normal and oxidant stress conditions, and provides an advantage to the parasite to develop resistance against currently used anti-trypanosomal drugs. TryS indispensability has been chemically validated with inhibitors that may be useful for drug combination therapy against Chagas disease.
BACKGROUND:Chagas cardiomyopathy, caused by Trypanosoma cruzi infection, continues to be a neglected illness, and has a major impact on global health. The parasite undergoes several stages of morphological and biochemical changes during its life cycle, and utilizes an elaborated antioxidant network to overcome the oxidants barrier and establish infection in vector and mammalian hosts. Trypanothione synthetase (TryS) catalyzes the biosynthesis of glutathione-spermidine adduct trypanothione (T(SH)2) that is the principal intracellular thiol-redox metabolite in trypanosomatids. METHODS AND RESULTS: We utilized genetic overexpression (TryShi) and pharmacological inhibition approaches to examine the role of TryS in T. cruzi proliferation, tolerance to oxidative stress and resistance to anti-protozoal drugs. Our data showed the expression and activity of TryS was increased in all morphological stages of TryShi (vs. control) parasites. In comparison to controls, the TryShi epimastigotes (insect stage) recorded shorter doubling time, and both epimastigotes and infective trypomastigotes of TryShi exhibited 36-71% higher resistance to H2O2 (50-1000 μM) and heavy metal (1-500 μM) toxicity. Treatment with TryS inhibitors (5-30 μM) abolished the proliferation and survival advantages against H2O2 pressure in a dose-dependent manner in both TryShi and control parasites. Further, epimastigote and trypomastigote forms of TryShi (vs. control) T. cruzi tolerated higher doses of benznidazole and nifurtimox, the drugs currently administered for acute Chagas disease treatment. CONCLUSIONS: TryS is essential for proliferation and survival of T. cruzi under normal and oxidant stress conditions, and provides an advantage to the parasite to develop resistance against currently used anti-trypanosomal drugs. TryS indispensability has been chemically validated with inhibitors that may be useful for drug combination therapy against Chagas disease.
Authors: P Azambuja; E S Garcia; P J Waniek; C S Vieira; M B Figueiredo; M S Gonzalez; C B Mello; D P Castro; N A Ratcliffe Journal: J Insect Physiol Date: 2016-11-17 Impact factor: 2.354
Authors: Florencia Irigoín; Lucía Cibils; Marcelo A Comini; Shane R Wilkinson; Leopold Flohé; Rafael Radi Journal: Free Radic Biol Med Date: 2008-06-12 Impact factor: 7.376
Authors: Carlos A Morillo; Jose Antonio Marin-Neto; Alvaro Avezum; Sergio Sosa-Estani; Anis Rassi; Fernando Rosas; Erick Villena; Roberto Quiroz; Rina Bonilla; Constança Britto; Felipe Guhl; Elsa Velazquez; Laura Bonilla; Brandi Meeks; Purnima Rao-Melacini; Janice Pogue; Antonio Mattos; Janis Lazdins; Anis Rassi; Stuart J Connolly; Salim Yusuf Journal: N Engl J Med Date: 2015-09-01 Impact factor: 91.245
Authors: Diego G Arias; Vanina E Marquez; María L Chiribao; Fernanda R Gadelha; Carlos Robello; Alberto A Iglesias; Sergio A Guerrero Journal: Free Radic Biol Med Date: 2013-05-08 Impact factor: 7.376
Authors: Andrea Medeiros; Diego Benítez; Ricarda S Korn; Vinicius C Ferreira; Exequiel Barrera; Federico Carrión; Otto Pritsch; Sergio Pantano; Conrad Kunick; Camila I de Oliveira; Oliver C F Orban; Marcelo A Comini Journal: J Enzyme Inhib Med Chem Date: 2020-12 Impact factor: 5.051